Diet that lowers insulin may cut breast cancer risk
NCT ID NCT06635005
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested whether a diet designed to lower insulin levels could reduce breast cancer risk in 34 high-risk women. The diet is rich in fruits, vegetables, whole grains, and plant protein, and low in animal protein and fat. The main goal was to see if women could stick to the diet, not yet to measure cancer outcomes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Low-insulinemic dietary pattern
- What this could lead to
- If successful, this diet could offer a practical way to lower breast cancer risk in high-risk women without medication.
- What could go wrong
- This is a small pilot study (34 women) testing feasibility, not effectiveness. The diet is complex and may be hard to follow long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
34 people
The number who actually took part.
- Started
-
Oct 2024
- Finished
-
Jan 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 45 years OR post-menopausal AND cis-gender women at study registration. * Overweight or World Health Organization (WHO) class 1 obese as defined by a body mass index (BMI) of 25 to 35 kg/m\^2. * High risk for breast cancer at the discretion of the physician, using standard definitions such as a Gail 5-year risk of ≥ 2% or Tyrer Cuzick version (v) 8.0 10-year risk of ≥ 5%. * Concurrent or prior use of endocrine therapy is allowed. Any dose or schedule change is not permitted for the duration of the study. * Currently established care or previously seen at the Ohio State University Comprehensive Cancer Center (OSUCCC) Stefanie Spielman Comprehensive Breast Center (SSCBC) high risk breast clinic. Exclusion Criteria: * Prior diagnosis of breast cancer within past 5 years. * Metastatic breast cancer (at study start or during study period). * BMI \> 35 kg/m\^2 or \< 25 kg/m\^2. * Pre-menopausal women or \< 45 years of age. * Assigned male at birth. * Uncontrolled intercurrent illness including lung disease, heart disease, metabolic disease; exacerbations for disease in past 8 weeks; unstable on medications for chronic conditions in past 6 weeks. This could affect compliance and engagement with study intervention. Change in anti-hyperglycemic or lipid lowering medications is best avoided for the duration of the study unless deemed necessary by treating provider or required for acute exacerbation of existing illness. * Type 1 diabetes mellitus (DM) or insulin dependent, or evidence of brittle diabetes. * Presence of food allergies or intolerances to wheat, nuts, seeds, fish, or dairy foods. * Currently on special diet for known metabolic or gastrointestinal disease, or planning to start a specific dietary regimen such as vegetarian, vegan, ketogenic, low-fat diets, etc. * Uncontrolled psychiatric illness/social situations that would limit compliance with study requirements. * Unwilling or unable to follow protocol requirements. * Pregnant, trying to get pregnant, or nursing. * Any condition which in the investigator's opinion deems the subject an unsuitable candidate to participate in this study. * Non-English speaking, as the teaching materials and educational sessions have not yet been translated into additional languages. * Prisoners or other institutionalized patients.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Compliance are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Virtual reality may soothe blood sugar spikes after meals
- Time-Restricted eating: a simple fix for better sleep and more movement?
- Smart toothbrush takes on gum disease: AI vs electric vs manual
- VR goggles ease children's pre-surgery jitters
- Could a few more months of antibiotics keep kidney transplant patients infection-free?
- Pre-Surgery boost: exercise and supplement may speed recovery for gynecologic cancer patients